Bank Vyatich

Bank Vyatich (PJSC) was registered by the Bank of Russia on April 19, 1994. Basic license for banking operations with funds in rubles and foreign currency (with the right to raise funds from individuals) without the right to bank operations with precious metals No. 2796.

History

2024: Recovery by the court of bank shares in favor of the state

The Seventh Cassation Court of General Jurisdiction decided to recover a block of shares in Ryazan Bank Vyatich and the pharmaceutical enterprise Uralbiopharm in favor of the state. The court rejected the cassation appeal of the owner of the Malika Gaysin assets. The decision was made on November 27, 2024.

According to Interfax, the Prosecutor General's Office proved Gaysin's violation of anti-corruption legislation during his deputy activities. The businessman illegally combined work in the State Duma with entrepreneurial activity from 1995 to 1999.

𝓲

Фото: Unsplash

Judicial acts were left unchanged, a complaint is being prepared to the Supreme Court of Russia, - said Gaysin's lawyer Anton Demchenko.

The supervisory authority established that the defendant controlled 99.995% of Uralbiopharm's shares through shell companies. For asset management, Vagran LLC and Aktai-M LLC, which served as nominal shareholders, were used.

The co-defendants in the case are seven persons, including Aydan Gaysin, Odis Gaysin, Rosa Golubeva and Gulsina Mullakhmetova. The legal defendants are Aktay-M, Vagran and Corona Thechet.

The initial decision on the nationalization of assets was made by the Leninsky District Court of Yekaterinburg in August 2023. A similar case on the nationalization of the Iset plant was the first case of the Supreme Court's cancellation of the decision to seize assets at the suit of the Prosecutor General's Office.

Bank Vyatich is in 307th place among Russian banks in terms of assets according to the Interfax-CEA rating for 9 months of 2024. Uralbiopharm, operating since 1930, is included in the plan for the privatization of federal property for 2024-2026.

The federal authorities intend to maintain the production of vital drugs at the facilities of Uralbiopharm after the transfer of the enterprise to state ownership.^[1]

Notes